Oramed Pharmaceuticals annual ebitda margin
2016
2017
2018
2019
2020
2021
2022
2023
2025
Oramed Pharmaceuticals EBITDA Margin Growth & History (ORMP)
Oramed Pharmaceuticals's ebitda margin was −748.35% for fiscal 2025.
View full Oramed Pharmaceuticals company overviewOramed Pharmaceuticals annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −748.35% | — |
| 2023 | 2023-12-31 | −1,162.16% | +337.65 pp |
| 2022 | 2022-12-31 | −1,499.82% | — |
| 2021 | 2021-08-31 | −893.30% | −459.72 pp |
| 2020 | 2020-08-31 | −433.58% | +107.41 pp |
| 2019 | 2019-08-31 | −540.99% | +11.11 pp |
| 2018 | 2018-08-31 | −552.10% | −113.75 pp |
| 2017 | 2017-08-31 | −438.36% | +1122.64 pp |
| 2016 | 2016-08-31 | −1,561.00% | — |
Oramed Pharmaceuticals quarterly ebitda margin
Q2.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q3.20
Q1.21
Q1.21
Q2.21
Q2.21
Q3.21
Q3.21
Q3.22
Q1.22
Q1.22
Q2.22
Q3.22
Q3.22
Q4.22
Q1.23
Q2.23
Q1.25
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q1 2025 | 2025-03-31 | −223.50% | — |
| Q2 2023 | 2023-06-30 | −554.75% | +1136.94 pp |
| Q1 2023 | 2023-03-31 | −776.43% | +911.41 pp |
| Q4 2022 | 2022-12-31 | −1,427.75% | +424.42 pp |
| Q3 2022 · Sep 30 | 2022-09-30 | −1,198.53% | −103.23 pp |
| Q3 2022 · Jun 30 | 2022-06-30 | −1,691.69% | −1035.31 pp |
| Q2 2022 | 2022-03-31 | −1,687.84% | −700.45 pp |
| Q1 2022 · Dec 31 | 2021-12-31 | −1,852.17% | −1100.43 pp |
| Q1 2022 · Nov 30 | 2021-11-30 | −1,194.07% | −329.82 pp |
| Q3 2022 · Sep 30 | 2021-09-30 | −1,095.31% | — |
| Q3 2021 · Jun 30 | 2021-06-30 | −656.38% | — |
| Q3 2021 · May 31 | 2021-05-31 | −894.27% | −560.79 pp |
| Q2 2021 · Mar 31 | 2021-03-31 | −987.39% | — |
| Q2 2021 · Feb 28 | 2021-02-28 | −728.57% | — |
| Q1 2021 · Dec 31 | 2020-12-31 | −751.74% | — |
| Q1 2021 · Nov 30 | 2020-11-30 | −864.24% | — |
| Q3 2020 | 2020-05-31 | −333.48% | +264.47 pp |
| Q4 2019 | 2019-08-31 | −343.76% | +166.45 pp |
| Q3 2019 | 2019-05-31 | −597.95% | +136.74 pp |
| Q2 2019 | 2019-02-28 | −535.44% | −20.70 pp |
| Q1 2019 | 2018-11-30 | −688.13% | −241.16 pp |
| Q4 2018 | 2018-08-31 | −510.21% | −48.72 pp |
| Q3 2018 | 2018-05-31 | −734.68% | −385.74 pp |
| Q2 2018 | 2018-02-28 | −514.74% | +35.84 pp |
| Q1 2018 | 2017-11-30 | −446.97% | −54.02 pp |
| Q4 2017 | 2017-08-31 | −461.49% | — |
| Q3 2017 | 2017-05-31 | −348.95% | — |
| Q2 2017 | 2017-02-28 | −550.57% | +978.23 pp |
| Q1 2017 | 2016-11-30 | −392.95% | — |
| Q2 2016 | 2016-02-29 | −1,528.80% | — |
Oramed Pharmaceuticals ebitda margin trends
Between the periods ended 2016-08-31 and 2025-12-31, Oramed Pharmaceuticals's ebitda margin increased from −1,561.00% to −748.35%, a change of +812.65 percentage points. The latest reported quarter, Q1 2025, shows −223.50%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Oramed Pharmaceuticals source filings ↗